The customer questioned a reactive alinity i anti-hbs result for a 37 year old male patient diagnosed with liver disease and spleen deficiency.Hbsag: >(b)(6) u/ml, reference range: 0-0.05iu/ml, reactive.Anti-hbs: (b)(6) miu/ml, reference range: 0-10 miu/ml, reactive (protective against hepatitis b viral infection).Hbeag: (b)(6) s/co, reference range: 0-1 s/co, nonreactive.Anti-hbe: (b)(6) s/co, reference range: >1 s/co, reactive.Anti-hbc:(b)(6) s/co, reference range: 0-1 s/co, reactive.The customer retested the sample using an elisa method, and results were reactive only for hbsag, anti-hbe and anti-hbc.There was a discrepancy in anti-hbs and hbeag results across platforms.No adverse impact to patient management was reported.
|
Information provided by the customer was reviewed and supports the complaint issue without indication for any additional issue.Trending review determined no adverse trend for the issue for the product.Historical complaint review determined there is normal complaint activity for the lot number.Device history record review did not show any potential non-conformances, or deviations.Labeling was reviewed and found to adequately address the issue under review.Worldwide data from abbottlink was reviewed and determined that patient median result for the lot is comparable with other lots in the field and within established baselines confirming no systemic issue for the lot.Based on the investigation, no deficiency for lot number 30022fn01 was identified.
|